GUO Yan, DING Li, HU Fupin, ZHU Demei, WANG Fu, TIAN Yueru, XU Yingchun, ZHANG Xiaojiang, ZHANG Fengbo, JI Ping, XIE Yi, XIAO Yuling, WANG Chuanqing, FU Pan, XU Yuanhong, HUANG Ying, SUN Ziyong, CHEN Zhongju, SUN Jingyong, CHEN Qing, CHU Yunzhuo, TIAN Sufei, HU Zhidong, LI Jin, YU Yunsong, FU Ying, SHAN Bin, XU Yunmin, GUO Sufang, WANG Yanyan, WEI Lianhua, LI Keke, ZHANG Hong, PAN Fen, HU Yunjian, AI Xiaoman, ZHUO Chao, GUAN Jing, GUO Dawen, ZHAO Jinying, YU Hua, HUANG Xiangning, LIU Wen'en, LI Yanming, JIN Yan, SHAO Chunhong, XU Xuesong, LI Wei, WANG Shanmei, MA Bing, ZHANG Lixia, MA Juan, ZHOU Shuping, ZHOU Yan, ZHU Lei, MENG Jinhua, DONG Fang, LÜ Zhiyong, HU Fangfang, SHEN Han, ZHOU Wanqing, JIA Wei, LI Gang, WU Jinsong, LU Yuemei, LI Jihong, SUN Qian, DUAN Jinju, KANG Jianbang, MA Xiaobo, ZHENG Yanqing, GUO Ruyi, ZHU Yan, CHEN Yunsheng, MENG Qing, WANG Shifu, HU Xuefei, FANG Hua, ZHANG Penghui, YU Bixia, GONG Ping, SHI Haixia, WEN Kaizhen, ZHAO Hongdong, YANG Xiuli, ZHAO Yiqin, LIAO Longfeng, WU Jinhua, GU Hongqin, JIANG Lin, HU Meifang, BAI Fangdong, FENG Jiao, YOU Lingling, WANG Dongmei, WANG Dong'e, LIU Yanyan, AN Yong, HUANG Wenhui, LI Juan, SHI Quangui, YANG Juan, Reziwaguli Abulimiti, HUANG Lili, SHAO Xuejun, REN Xiaoyan, LI Dong, ZHANG Qun, CHEN Xue, LI Rihai, XU Jieli, GAO Kaijie, XU Lu, LIN Lin, ZHANG Zhuo, LIU Jianlong, FU Min, GUO Yinghui, ZHANG Wenchao, WANG Zengguo, JIA Kai, XIA Yun, SUN Shan, YANG Huimin, MIAO Yan, WANG Jianping, ZHOU Mingming, ZHANG Shihai, LIU Hongjuan, CHEN Nan, LI Chan, KOU Cunshan, XUE Shunhong, SHEN Jilu, MEN Wanqi, WANG Peng, ZHANG Xiaowei, ZENG Xiaoyan, LI Wen, GENG Yan, LIU Zeshi, WU Xiaoyan, LI Xiaosi
Abstract (
)
Download PDF (
)
Knowledge map
Save
Objective To monitor the susceptibility of clinical isolates to antimicrobial agents in healthcare facilities in major regions of China in 2024. Methods Clinical isolates from 74 hospitals in China were tested for antimicrobial susceptibility using a unified protocol based on disc diffusion method or automated testing systems. Results were interpreted using the 2024 Clinical & Laboratory Standards Institute (CLSI) breakpoints. Results A total of 458 271 clinical isolates were collected in 2024, of which 28.3% were gram-positive and 71.7% were gram-negative. The prevalence of methicillin-resistant strains in Staphylococcus aureus, Staphylococcus epidermidis and other coagulase-negative Staphylococcus species (excluding Staphylococcus pseudintermedius and Staphylococcus schleiferi) (MRSA, MRSE and MRCNS) were 28.4%, 76.5%, and 70.2%, respectively. No vancomycin-resistant strains were found. The resistance rates of Enterococcus faecalis and Enterococcus faecium to high-concentration gentamicin were 36.6% and 39.7%, respectively. A few vancomycin-resistant strains were identified in both E. faecalis and E. faecium. E. faecium showed higher resistance rates to most antimicrobials compared to E. faecalis. The prevalence of penicillin-nonsusceptible strains (PISP and PRSP) among non-meningitis Streptococcus pneumoniae isolated from children and adults was 0.1% and 1.0%, respectively. The resistance rate to carbapenems was lower than 15.0% for most Enterobacterales species except for Klebsiella, 21.3%, and 22.1% of which were resistant to imipenem and meropenem, respectively. Most Enterobacterales isolates were highly susceptible to tigecycline (≤3.1% resistant) and colistin (≤4.2% resistant). The resistance rates to imipenem and meropenem were 21.3% and 17.3% for Pseudomonas aeruginosa, respectively, 64.5% and 64.7% for Acinetobacter baumannii, respectively. Conclusions In 2024, the antimicrobial resistance of clinical bacterial isolates was still serious. Clinicians should rationally select antimicrobial agents based on the results of antimicrobial resistance surveillance to effectively control the development of bacterial resistance.
